Clinical trials: HTN, open to volunteers
Hypertension
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-339 in healthy volunteers.
- Trial name
- NCT07748702
- Testing
- CKD-339, D311, D107
- Where
- South Korea
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Diabete Type 2
Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination)…
- Trial name
- NCT07552389
- Testing
- Test group, Exploratory test group, Control group 1
- Where
- South Korea
- Volunteers
- 228 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Primary Open Angle Glaucoma
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
The purpose of this study is to collect safety and performance data on the PRESERFLO™ MicroShunt XI in patients diagnosed with primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with…
- Trial name
- NCT07235592
- Testing
- Microshunt XI
- Where
- 12 sites in Austria, Belgium and 6 more
- Volunteers
- 112 people
- Sponsor
- Santen SAS
Primary Open-Angle Glaucoma, Optic Nerve Injury
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma…
- Trial name
- NCT07777861
- Testing
- G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml
- Where
- 9 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.
Open Angle Glaucoma
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or competitor device in reducing IOP at 12 months postoperatively.
- Trial name
- NCT06246136
- Testing
- ELIOS, Competitor Device
- Where
- 16 sites in Belgium, France and 4 more
- Volunteers
- 194 people
- Sponsor
- Elios Vision, Inc.
Preeclampsia (PE)
Non-Invasive Preeclampsia Screening and Biobank
Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.
- Trial name
- NCT06643741
- Where
- 21 sites in United States
- Volunteers
- 6,550 people, healthy volunteers welcome
- Sponsor
- Sequenom, Inc.
Glaucoma
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Trial name
- NCT07495852
- Testing
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- Glaukos Corporation
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Trial name
- NCT07660796
- Testing
- HCP1803-3, HCP1803-4, RLD2001-1
- Where
- South Korea
- Volunteers
- 256 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pulmonary Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Researchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH).
- Trial name
- CHORUS (NCT07839585)
- Testing
- Sotatercept
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Disease and Hypertension
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in…
- Trial name
- BaxDuo-Pacific (NCT06742723)
- Testing
- Baxdrostat/dapagliflozin
- Where
- 771 sites in United States, Argentina and 40 more
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension.
- Trial name
- BAHAMA (NCT07675824)
- Testing
- REGN22530
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Regeneron Pharmaceuticals
Hypertension, Hypertension,Essential
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
To obtain an assessment of the efficacy and safety of renal denervation by dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter in hypertensive subjects in the absence of antihypertensive…
- Trial name
- RADAR (NCT07083765)
- Testing
- Dehydrated Alcohol Injection, USP
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Ablative Solutions, Inc.
Ascites, Variceal Bleeding
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension.
- Conditions
- Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
- Trial name
- VIATIPS (NCT07390344)
- Testing
- GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm)
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- W.L.Gore & Associates
Hypertension, MTHFR 677 TT Genotype
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype.
- Trial name
- CSPPT2-TT (NCT04974151)
- Testing
- Amlodipine besylate, Amlodipine besylate And Folic Acid, 5-methyltetrahydrofolate (5-MTHF)
- Where
- 20 sites in China
- Volunteers
- 24,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertension
The "Global Paradise System" Registry
The GPS Registry is a multi-centre, single-arm, non-interventional (observational) registry. In addition to collecting data from patients treated as per standard clinical practice, the Registry will also regularly collect…
- Trial name
- GPSRegistry (NCT05027685)
- Testing
- The Paradise Ultrasound Renal Denervation System
- Where
- 55 sites in Austria, Belgium and 7 more
- Volunteers
- 3,000 people
- Sponsor
- ReCor Medical, Inc.
Hypertensive Disease
SMART-IC-Pilot Study
This small-scale, proof-of-concept pilot study aims to obtain preliminary evidence of msRDN procedural safety, feasibility, and short-term efficacy in patients with hypertension without medication therapy, to adequately plan an…
- Trial name
- SMART-IC-Pilot (NCT07336433)
- Testing
- The SymPioneer G2 Mapping/Selective Renal Denervation Device and SyMapCath Catheter II
- Where
- China
- Volunteers
- 15 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Hypertension, Hypertension, Systolic
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure…
- Conditions
- Hypertension, Hypertension, Systolic, Hypertension, Essential
- Trial name
- BACKBEAT (NCT06059638)
- Testing
- Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Where
- 131 sites in United States, Australia and 13 more
- Volunteers
- 316 people
- Sponsor
- Orchestra BioMed, Inc
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT07421401
- Testing
- BR1015-A, BR1015-3, BR1015-2
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.